Ulrika Marking
YOU?
Author Swipe
View article: Risk factors for hospitalization and death due to COVID-19 during endemic Omicron circulation, a population-based cohort study
Risk factors for hospitalization and death due to COVID-19 during endemic Omicron circulation, a population-based cohort study Open
Also, in the current Omicron endemicity, advanced age remains the strongest risk factor for hospitalization and death due to COVID-19, accompanied by advanced comorbidity and care dependency. These findings can guide public health recommen…
View article: Overview of approved COVID-19 vaccines in the EU, recommendations for use in Sweden and vaccine uptake over time
Overview of approved COVID-19 vaccines in the EU, recommendations for use in Sweden and vaccine uptake over time Open
Objective: The aim of this review is to describe the regulatory background of the COVID-19 vaccines, the national recommendations for use issued and vaccine uptake in Sweden. It includes an overview of licensing and relevant safety aspects…
View article: Risk factors for hospitalisation and death due to COVID-19 during endemic Omicron circulation, a population-based cohort study
Risk factors for hospitalisation and death due to COVID-19 during endemic Omicron circulation, a population-based cohort study Open
Background Knowledge about risk factors for hospitalisation and death due to COVID-19 during the Omicron period, beyond the initial Omicron wave, remains limited. Therefore, to support vaccination strategies and antiviral treatment recomme…
View article: Teamwork makes the dream work : systemic and mucosal immunity in shaping protection against SARS-CoV-2
Teamwork makes the dream work : systemic and mucosal immunity in shaping protection against SARS-CoV-2 Open
COVID-19 triggered an unprecedented scientific response, and although knowledge gaps persist, large parts of the world had access to efficacious vaccines only a year after the virus first appeared. A detailed understanding of mechanisms of…
View article: Teamwork makes the dream work : systemic and mucosal immunity in shaping protection against SARS-CoV-2
Teamwork makes the dream work : systemic and mucosal immunity in shaping protection against SARS-CoV-2 Open
COVID-19 triggered an unprecedented scientific response, and although knowledge gaps persist, large parts of the world had access to efficacious vaccines only a year after the virus first appeared. A detailed understanding of mechanisms of…
View article: Regional differences in COVID-19 vaccine uptake and their determinants among Swedish older adults
Regional differences in COVID-19 vaccine uptake and their determinants among Swedish older adults Open
Regional differences in vaccine uptake emerged for subsequent doses as national prioritization and coordination was relaxed. Our findings underscore the importance of minimizing regional variation through targeted interventions.
View article: Logistics for Rapid Isolation of Viruses From Humans
Logistics for Rapid Isolation of Viruses From Humans Open
An important aspect of microbiological surveillance is the ability to access live viruses for microneutralization assays, which enables the study of viral characteristics and mechanisms in vitro and production of positive controls for diag…
View article: Comparison of SARS-CoV-2 spike-specific IgA and IgG in nasal secretions, saliva and serum
Comparison of SARS-CoV-2 spike-specific IgA and IgG in nasal secretions, saliva and serum Open
Introduction Several novel vaccine platforms aim at mucosal immunity in the respiratory tract to block SARS-CoV-2 transmission. Standardized methods for mucosal sample collection and quantification of mucosal antibodies are therefore urgen…
View article: Humoral immune responses to the monovalent XBB.1.5-adapted BNT162b2 mRNA booster
Humoral immune responses to the monovalent XBB.1.5-adapted BNT162b2 mRNA booster Open
Continued SARS-CoV-2 evolution and immune escape necessitated the development of updated vaccines, and a monovalent vaccine incorporating the XBB.1.5 variant spike protein is currently being rolled out. Amidst the emergence of the highly m…
View article: Anti-Spike Mucosal IgA Protection against SARS-CoV-2 Omicron Infection
Anti-Spike Mucosal IgA Protection against SARS-CoV-2 Omicron Infection Open
nated, 0 to 13 days, 14 to 27 days, 1 to 2 months, 3 to 4 months, 5 to 6 months, 7 to 8 months, or ≥9 months).Among the patients who had received two doses of vaccine, waning of effectiveness against hospitalization was evident as early as…
View article: Infection Rate of SARS-CoV-2 in Asymptomatic Healthcare Workers, Sweden, June 2022
Infection Rate of SARS-CoV-2 in Asymptomatic Healthcare Workers, Sweden, June 2022 Open
Given the recent surge in SARS-CoV-2 Omicron infections, we performed a quantitative PCR screening survey during June 28-29, 2022, in Stockholm, Sweden, to investigate SARS-CoV-2 point prevalence in a group with high exposure risk. Results…
View article: Correlates of protection, viral load trajectories and symptoms in BA.1, BA.1.1 and BA.2 breakthrough infections in triple vaccinated healthcare workers
Correlates of protection, viral load trajectories and symptoms in BA.1, BA.1.1 and BA.2 breakthrough infections in triple vaccinated healthcare workers Open
Background Booster vaccine doses offer protection against severe COVID-19 caused by omicron but are less effective against infection. Characteristics such as serological correlates of protection, viral abundance, and clearance of omicron i…
View article: Duration of SARS-CoV-2 Immune Responses Up to Six Months Following Homologous or Heterologous Primary Immunization with ChAdOx1 nCoV-19 and BNT162b2 mRNA Vaccines
Duration of SARS-CoV-2 Immune Responses Up to Six Months Following Homologous or Heterologous Primary Immunization with ChAdOx1 nCoV-19 and BNT162b2 mRNA Vaccines Open
Heterologous primary immunization against SARS-CoV-2 is part of applied recommendations. However, little is known about duration of immune responses after heterologous vaccine regimens. To evaluate duration of immune responses after primar…
View article: Impact of SARS‐CoV‐2 infection on vaccine‐induced immune responses over time
Impact of SARS‐CoV‐2 infection on vaccine‐induced immune responses over time Open
Objective To determine the long‐term impact of prior SARS‐CoV‐2 infection on immune responses after COVID‐19 vaccination. Methods Using longitudinally collected blood samples from the COMMUNITY study, we determined binding (WHO BAU mL −1 )…
View article: Impact of SARS-CoV-2 infection on vaccine-induced immune responses over time
Impact of SARS-CoV-2 infection on vaccine-induced immune responses over time Open
People with previous SARS-CoV-2 infection mount potent immune responses to COVID-19 vaccination, but long-term effects of prior infection on these immune responses are unknown. We investigated the long-term impact of prior SARS-CoV-2 infec…
View article: An evaluation of a FluoroSpot assay as a diagnostic tool to determine SARS-CoV-2 specific T cell responses
An evaluation of a FluoroSpot assay as a diagnostic tool to determine SARS-CoV-2 specific T cell responses Open
Numerous assays evaluating serological and cellular responses have been developed to characterize immune responses against SARS-CoV-2. Serological assays are both cost- and time-effective compared to cellular assays, but cellular immune re…
View article: Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID‐19
Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID‐19 Open
Background Emerging data support detectable immune responses for months after severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection and vaccination, but it is not yet established to what degree and for how long protection …
View article: Neutralization of VOCs including Delta one year post COVID-19 or vaccine
Neutralization of VOCs including Delta one year post COVID-19 or vaccine Open
Background SARS-CoV-2 variants, such as Alpha, Beta, Gamma and Delta, are raising concern about the efficiency of neutralizing antibodies (NAb) induced by wild-type infection or vaccines based on the wild-type spike. Methods We determined …
View article: Antibody Responses After a Single Dose of ChAdOx1 nCoV-19 Vaccine in Healthcare Workers Previously Infected with SARS-CoV-2
Antibody Responses After a Single Dose of ChAdOx1 nCoV-19 Vaccine in Healthcare Workers Previously Infected with SARS-CoV-2 Open
Background Recent reports demonstrate robust serological responses to a single dose of messenger RNA (mRNA) vaccines in individuals previously infected with SARS-CoV-2. Data on immune responses following a single-dose adenovirus-vectored v…